Gilead’s Jyseleca (filgotinib) Receives the MHLW’s Approval for Rheumatoid Arthritis in Japan

 Gilead’s Jyseleca (filgotinib) Receives the MHLW’s Approval for Rheumatoid Arthritis in Japan

Gilead’s Jyseleca (filgotinib) Receives the MHLW’s Approval for Rheumatoid Arthritis in Japan

Shots:

  • The approval is based on two clinical trials (P-III FINCH and P-II DARWIN) programs assessing Jyseleca in 3,500+ patients across a range of RA patient populations, including patients new to treatment and those who have demonstrated inadequate response to treatment with SOC including biologic DMARDs. Gilead and Eisai will jointly commercialize Jyseleca across Japan
  • Results: improvement in clinical signs and symptoms, decreased disease activity and lessened the structural damage progression in their joints. Across the FINCH studies, Jyseleca demonstrated a consistent safety profile, and the frequency of AEs was comparable to control groups
  • Jyseleca is a JAK1 inhibitor for the treatment of RA, in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Yahoo Finance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post